Diflucan Capsule 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are absorbed rapidly and almost completely; therefore, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. 1. Vaginal candidiasis: Administer 150 mg of fluconazole orally as a single dose. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (e.g., peritoneal, endocardial, pulmonary, and urinary tract infections): The usual dose is 400 mg as a single dose on the first day, followed by 200 mg once daily from the next day. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined based on clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose is 400 mg as a single dose on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment is determined by clinical and mycological response, but treatment should generally continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg once daily indefinitely after the patient has completed initial therapy. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg once daily according to the patient's risk of developing a fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those undergoing bone marrow transplantation who are expected to have severe or prolonged neutropenia. In these patients, administer 400 mg starting 5-6 days before the expected onset of neutropenia, and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or higher. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until uninfected new nails have grown). New fingernails usually take 3-6 months to grow, and toenails take 6-12 months; growth rate may vary between individuals and with age. Even after successful treatment with long-term administration, nails may sometimes remain damaged. Dermatophyte infections, including athlete's foot (tinea pedis), ringworm of the body (tinea corporis), jock itch (tinea cruris), and cutaneous candidiasis: The usual dose is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks, depending on the response. For pityriasis versicolor, administer 50 mg once daily for 2-4 weeks. Patients with normal renal function should generally receive the usual adult dose. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. This medicine is excreted mainly in the urine unchanged. No dosage adjustment is necessary for a single dose. If multiple doses are required, administer the usual dose only on the first day and adjust the dose from the following day as follows: Creatinine clearance (mL/min) > 50: 100 % of the usual dose ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients undergoing hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This medication should not be administered to certain patients. For example, individuals allergic to this drug or similar drugs, pregnant women or those who may become pregnant, as well as nursing mothers should not take this medication. Additionally, patients already taking certain medications that may pose risks when combined with this drug should avoid it. Since this medication contains lactose, it should not be given to patients with a genetic problem that prevents lactose digestion. Special caution is advised when using this medication in patients with impaired renal or liver function, those with heart disease or at risk for arrhythmia. Moreover, this drug may interact with several other medications, so anyone taking other medications must inform their healthcare provider and dosage adjustment or monitoring may be necessary. While this drug is generally well-tolerated, it can rarely affect the blood, liver, or kidneys, and skin rashes or allergic reactions may occur. During pregnancy, the use of this drug can be harmful to the fetus, so it should not be used if planning for or during pregnancy, and effective contraception should be implemented during and for some time after treatment. It is also advisable to avoid administering this medication to breastfeeding mothers since it can be excreted in breast milk. The safety of this drug in young children, especially infants under 6 months old, has not been established, so it should only be used when absolutely necessary. While taking this medication, dizziness or seizures may occur, so caution is needed while driving or operating machinery. In case of overdose, hallucinations or abnormal behavior may occur, and immediate medical attention is required.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsades de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, elevated serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, hepatic failure, hepatic necrosis, hepatitis, hepatocellular injury, rash, itching, urticaria, increased sweating, drug eruption, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, alopecia, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, malaise, weakness, fever, adrenal insufficiency, hallucinations, psychomotor agitation

This medication can be sensitive to air and moisture, so it should be stored in a sealed container. It is important to maintain the storage temperature between 1 and 30 degrees Celsius. This will help preserve the effectiveness of the medication for a longer period.

Appearance

[For domestic use] Capsules with white powder filling, dark blue upper part, light blue lower part. [For export 1] Capsules with white powder filling, dark blue upper part, white lower part. [For export 2] Capsules with white powder filling, dark blue part.

Package unit

For domestic use: 30 capsules/bottle, 100 capsules/bottle For export: 4 capsules/PTP